No Detail Found!

Curcumin as a potent inhibitor molecule for mixed lineage kinase: a molecular docking and in vitro study for potential cancer treatment

Author(s)
Misbahuddin M Rafeeq Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University,Jeddah, 21589, Kingdom of,Saudi Arabia
Saad Alghamdi Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
Ahmed H Qasem Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
Samah J. Almehmadi Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
Issa Saad Al-Moraya Forensic Medicine Center, Ministry of Health,,Saudi Arabia
Afnan Alkathiri Medical Genetics, Laboratory Medicine Department, Faculty of Applied Medical Sciences, Albaha University,Albaha, Kingdom of,Saudi Arabia
Reema Mohammed Almotairi Medical Laboratory Technology Department, Faculty of Applied medical sciences, University of Tabuk, Saudi Arabia; Prince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia
Qamre Alam Molecular Genomics and Precision Medicine Department, ExpressMed Diagnostics and Research, Block, 359, Zinj, Kingdom of Bahrain
Abstract
Mixed lineage kinases (MLK) have emerged as potential therapeutic targets for the treatment of cancer, as they are often overexpressed or dysregulated in cancer cells, leading to aberrant signaling pathways that promote cancer cell proliferation, survival, and metastasis. Targeting MLK using small molecule inhibitors represents a promising therapeutic strategy for various diseases, and ongoing research efforts aim to develop novel and more effective MLK inhibitors with improved target specificity and reduced off-target effects. Here, we proposed to study the binding affinity and effect of curcumin on the activity of MLK. We employed molecular docking, fluorescence-based inhibition assay, and kinase activity assay to determine the binding affinity and inhibition of MLK. Further, MTT assay was used to determine the effect of curcumin on the viability of Hek 293 cells and to determine the IC50 concentration of curcumin which can be used for cancer cell line experiments. Molecular docking results showed binding affinity of -7.0 kcal/mol of curcumin and reflected it as potent inhibitor of MLK. Further, fluorescence inhibition and kinase activity assays validation the curcumin as potent inhibitor of MLK. MTT assay results showed that there was no significant effect of increasing concentrations of curcumin on the viability of Hek 293 cells. The IC50 concentration of curcumin was found as 12.0 ± 1.99 µM. In conclusion, the findings of this study highlight the importance of using a combination of in silico and in vitro techniques to evaluate the potential of natural compounds as therapeutic agents. Here we report curcumin as potent inhibitor molecule for MLK.
Publication Details
Page(s) 549-556
DOI DOI not available
Published Journal: Bioscience Research, Volume: 20, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Cancer, Inhibition, Curcumin, molecular docking, Mixed Lineage Kinase
0

Citations

0

Downloads

65

Views